Physician profile
Beth A Degeyter
NPI 1366157737
$2,702.10
in general payments reported to CMS, 2019-2025
25 companies · $1,052 in 2025
The $1,052 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $241 · 2024: $1,409 · 2025: $1,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,702.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $508.28 | 2023-2025 | |
| Axsome Therapeutics, INC. | $241.08 | 2025 | Auvelity |
| Astellas Pharma US INC | $230.64 | 2024-2025 | Veozah |
| Pfizer INC. | $213.44 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $207.57 | 2023-2025 | Airsupra, Breztri |
| Revance Therapeutics, INC. | $173.02 | 2024 | Daxi, Daxxify |
| Lilly USA, LLC | $167.43 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $150.53 | 2023-2025 | Cologuard Collection Kit |
| Itamar Medical INC | $143.85 | 2024-2025 | Watchpatone |
| Novo Nordisk INC | $134.52 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.47 | 2023-2025 | Xifaxan, Trulance |
| Acella Pharmaceuticals, LLC | $60.58 | 2024 | NP Thyroid 60 |
| Kowa Pharmaceuticals America, INC. | $57.30 | 2024-2025 | Zoryve |
| Glaxosmithkline, LLC. | $54.87 | 2024-2025 | Shingrix, Arexvy |
| Lundbeck LLC | $50.89 | 2024-2025 | Vyepti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $40.58 | 2023-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $29.60 | 2024 | Trintellix |
| Millicent US INC | $29.10 | 2025 | Intrarosa |
| Tolmar, INC. | $22.15 | 2024 | |
| Amneal Pharmaceuticals LLC | $20.44 | 2025 | Unithroid |
| Nestle Healthcare Nutrition INC. | $18.68 | 2023 | |
| Bausch Health US, LLC | $15.93 | 2023 | Wellbutrin, Aplenzin |
| Ibsa Pharma INC. | $14.95 | 2024 | Tirosint, Licart |
| Currax Pharmaceuticals LLC | $14.59 | 2025 | Contrave |
| Phathom Pharmaceuticals, INC. | $13.61 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Degeyter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.